<p>MaxCyte, Inc. (NASDAQ:MXCT - 獲取免費報告) 在一月份的空頭頭寸大幅增長。截至 1 月 30 日，空頭頭寸總計為 3,881,689 股，比 1 月 15 日的 2,503,062 股增長了 55.1%。目前，該股票的 3.8% 股份被做空。根據平均每日交易量 1,116,399 股，空頭頭寸比率目前為 3.5 天。根據平均每日交易量 1,116,399 股，空頭頭寸比率目前為 3.5 天。目前，該股票的 3.8% 股份被做空。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>幾位研究分析師最近對該公司發表了看法。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 MaxCyte 股票的 “賣出（e+）” 評級。華爾街 Zen 在 2 月 7 日的報告中將 MaxCyte 的評級從 “賣出” 上調至 “持有”。兩位股票研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，MaxCyte 目前的平均評級為 “持有”，平均目標價格為 7.00 美元。</p>
<p><strong>閲讀我們關於 MXCT 的最新股票報告</strong></p>
<h2>MaxCyte 價格表現</h2>
<p>NASDAQ:MXCT 的股票在週五交易中下跌 0.01 美元，報 0.72 美元。該公司交易了 1,262,423 股，相比其平均交易量 1,382,774 股。MaxCyte 的 12 個月低點為 0.68 美元，12 個月高點為 4.32 美元。該股票的市值為 7676 萬美元，市盈率為-1.64，貝塔值為 1.21。該公司的 50 日移動平均價格為 1.28 美元，200 日移動平均價格為 1.48 美元。</p>
<p>MaxCyte (NASDAQ:MXCT - 獲取免費報告) 最近在 11 月 12 日公佈了其財報。該公司報告季度每股收益為（0.12 美元），低於分析師一致預期的（0.11 美元）0.01 美元。MaxCyte 的淨利潤率為-132.57%，股本回報率為-23.50%。該季度的收入為 641 萬美元，而分析師預期為 837 萬美元。整體來看，股票研究分析師預計 MaxCyte 在本年度將發佈-0.42 美元的每股收益。</p>
<h2>機構投資者對 MaxCyte 的看法</h2>
<p>幾家機構投資者最近對該股票的持倉進行了調整。Mirabella Financial Services LLP 在第二季度將其在 MaxCyte 的持股增加了 78.4%。Mirabella Financial Services LLP 目前擁有 660 萬股該公司的股票，價值 1438.8 萬美元，此前在上一季度又購買了 290 萬股。Kennedy Capital Management LLC 在第三季度獲得了 MaxCyte 的新頭寸，價值 333 萬美元。AXA S.A.在第二季度將其在 MaxCyte 的持倉增加了 123.2%。AXA S.A.目前擁有 2202378 股該公司的股票，價值 480.1 萬美元，此前在上一季度又購買了 1215481 股。Jacobs Levy Equity Management Inc.在第四季度獲得了 MaxCyte 的新股份，價值 159.4 萬美元。最後，Willis Investment Counsel 在第三季度將其在 MaxCyte 的持倉增加了 126.8%。Willis Investment Counsel 目前擁有 862758 股該公司的股票，價值 136.3 萬美元，此前在上一季度又購買了 482287 股。68.81% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>關於 MaxCyte</h2>
<p>(獲取免費報告)</p>
<p>MaxCyte, Inc NASDAQ: MXCT 是一家臨牀階段的細胞治療平台公司，開發和商業化專有的流動電穿孔技術，以將大分子輸送到活細胞中。該公司的儀器和耗材旨在支持細胞治療的研究、臨牀前開發和臨牀規模生產，涵蓋多種模式，包括工程化 T 細胞、自然殺傷（NK）細胞和誘導多能幹細胞（iPSC）治療。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 MaxCyte 更好</li>
<li>認為你錯過了銀？你錯了。這就是原因。</li>
<li>你的銀行賬户不再安全</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>硅谷內部人士暗示 12 個月的 AI 警告</li>
<li>現在購買這隻股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 MaxCyte 嗎？</h2>
<p>在你考慮 MaxCyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 MaxCyte 並不在名單上。</p>
<p>雖然 MaxCyte 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

MXCT

<p>MaxCyte, Inc.（納斯達克代碼：MXCT）在 1 月份的空頭頭寸顯著增加，增長了 55.1%，達到 3,881,689 股。目前，該公司的股票中有 3.8% 被做空，基於平均交易量 1,116,399 股，覆蓋天數比率為 3.5 天。分析師對該股票的評級不一，平均目標價格為 7.00 美元。MaxCyte 報告的季度每股收益為（0.12 美元），未達到預期，收入為 641 萬美元，低於預期。機構投資者持有 68.81% 的股份</p>

<p>MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 3,881,689 shares, a growth of 55.1% from the January 15th total of 2,503,062 shares. Currently, 3.8% of the shares of the stock are short sold. Based on an average daily volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Based on an average daily volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Currently, 3.8% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>MaxCyte, Inc. (NASDAQ:MXCT - 獲取免費報告) 在一月份的空頭頭寸大幅增長。截至 1 月 30 日，空頭頭寸總計為 3,881,689 股，比 1 月 15 日的 2,503,062 股增長了 55.1%。目前，該股票的 3.8% 股份被做空。根據平均每日交易量 1,116,399 股，空頭頭寸比率目前為 3.5 天。根據平均每日交易量 1,116,399 股，空頭頭寸比率目前為 3.5 天。目前，該股票的 3.8% 股份被做空。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of MaxCyte in a research report on Monday, December 29th. Wall Street Zen upgraded MaxCyte from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, February 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, MaxCyte presently has an average rating of &#34;Hold&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該公司發表了看法。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 MaxCyte 股票的 “賣出（e+）” 評級。華爾街 Zen 在 2 月 7 日的報告中將 MaxCyte 的評級從 “賣出” 上調至 “持有”。兩位股票研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，MaxCyte 目前的平均評級為 “持有”，平均目標價格為 7.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on MXCT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 MXCT 的最新股票報告</strong></p>
</div><h2>MaxCyte Price Performance</h2>
<div class="lb-trans"><h2>MaxCyte 價格表現</h2>
</div><p>Shares of NASDAQ:MXCT traded down $0.01 during trading on Friday, hitting $0.72. 1,262,423 shares of the company were exchanged, compared to its average volume of 1,382,774. MaxCyte has a 12-month low of $0.68 and a 12-month high of $4.32. The stock has a market capitalization of $76.76 million, a P/E ratio of -1.64 and a beta of 1.21. The firm's 50 day moving average price is $1.28 and its 200-day moving average price is $1.48.</p>
<div class="lb-trans"><p>NASDAQ:MXCT 的股票在週五交易中下跌 0.01 美元，報 0.72 美元。該公司交易了 1,262,423 股，相比其平均交易量 1,382,774 股。MaxCyte 的 12 個月低點為 0.68 美元，12 個月高點為 4.32 美元。該股票的市值為 7676 萬美元，市盈率為-1.64，貝塔值為 1.21。該公司的 50 日移動平均價格為 1.28 美元，200 日移動平均價格為 1.48 美元。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. As a group, equities research analysts anticipate that MaxCyte will post -0.42 EPS for the current year.</p>
<div class="lb-trans"><p>MaxCyte (NASDAQ:MXCT - 獲取免費報告) 最近在 11 月 12 日公佈了其財報。該公司報告季度每股收益為（0.12 美元），低於分析師一致預期的（0.11 美元）0.01 美元。MaxCyte 的淨利潤率為-132.57%，股本回報率為-23.50%。該季度的收入為 641 萬美元，而分析師預期為 837 萬美元。整體來看，股票研究分析師預計 MaxCyte 在本年度將發佈-0.42 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MaxCyte</h2>
<div class="lb-trans"><h2>機構投資者對 MaxCyte 的看法</h2>
</div><p>Several institutional investors have recently made changes to their positions in the stock. Mirabella Financial Services LLP increased its holdings in MaxCyte by 78.4% in the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company's stock valued at $14,388,000 after buying an additional 2,900,000 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in MaxCyte during the third quarter worth $3,330,000. AXA S.A. boosted its position in MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company's stock worth $4,801,000 after purchasing an additional 1,215,481 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in MaxCyte in the fourth quarter valued at $1,594,000. Finally, Willis Investment Counsel increased its position in shares of MaxCyte by 126.8% in the third quarter. Willis Investment Counsel now owns 862,758 shares of the company's stock valued at $1,363,000 after buying an additional 482,287 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近對該股票的持倉進行了調整。Mirabella Financial Services LLP 在第二季度將其在 MaxCyte 的持股增加了 78.4%。Mirabella Financial Services LLP 目前擁有 660 萬股該公司的股票，價值 1438.8 萬美元，此前在上一季度又購買了 290 萬股。Kennedy Capital Management LLC 在第三季度獲得了 MaxCyte 的新頭寸，價值 333 萬美元。AXA S.A.在第二季度將其在 MaxCyte 的持倉增加了 123.2%。AXA S.A.目前擁有 2202378 股該公司的股票，價值 480.1 萬美元，此前在上一季度又購買了 1215481 股。Jacobs Levy Equity Management Inc.在第四季度獲得了 MaxCyte 的新股份，價值 159.4 萬美元。最後，Willis Investment Counsel 在第三季度將其在 MaxCyte 的持倉增加了 126.8%。Willis Investment Counsel 目前擁有 862758 股該公司的股票，價值 136.3 萬美元，此前在上一季度又購買了 482287 股。68.81% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>About MaxCyte</h2>
<div class="lb-trans"><h2>關於 MaxCyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.</p>
<div class="lb-trans"><p>MaxCyte, Inc NASDAQ: MXCT 是一家臨牀階段的細胞治療平台公司，開發和商業化專有的流動電穿孔技術，以將大分子輸送到活細胞中。該公司的儀器和耗材旨在支持細胞治療的研究、臨牀前開發和臨牀規模生產，涵蓋多種模式，包括工程化 T 細胞、自然殺傷（NK）細胞和誘導多能幹細胞（iPSC）治療。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Silicon Valley insiders hint at 12-month AI warning</li>
<li>Buy This Stock Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 MaxCyte 更好</li>
<li>認為你錯過了銀？你錯了。這就是原因。</li>
<li>你的銀行賬户不再安全</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>硅谷內部人士暗示 12 個月的 AI 警告</li>
<li>現在購買這隻股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 MaxCyte 嗎？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MaxCyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 MaxCyte 並不在名單上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MaxCyte 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

MaxCyte, Inc.（納斯達克股票代碼：MXCT）的空頭頭寸在 1 月份上升了 55.1%